NeuBase Therapeutics Appoints Todd P. Branning Chief Financial Officer

 Source:  NeuBase Therapeutics, Inc. 1/10/2022

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today the appointment of Todd P. Branning as Chief Financial Officer (CFO). Mr. Branning has more than 25 years of experience leading corporate finance and accounting, tax, financial planning and analysis, and investor relations for several publicly traded pharmaceutical companies.

“Todd brings the highest level of sophistication in finance to NeuBase,” said Dietrich A. Stephan, Ph.D., Founder, CEO and Chairman of NeuBase. “We are a truly unique genetic medicines platform company with a technology that is specifically designed to directly and precisely drug the double-helix of the human genome and a new therapeutic modality to address root causality across rare and common diseases. Enlightened leadership, creativity, and clarity of thought are essential in developing any new transformational solution. Thus, I am delighted to welcome Todd to the executive team as we begin our next phase of growth with the filing of our first INDs and scaling our therapeutic pipeline.”

“NeuBase has the potential to transform and consolidate the pharmaceutical industry as we know it by bringing forward a ‘final generation’ of genetic medicines in a scalable manner,” said Mr. Branning. “I am excited to join NeuBase at this important time in the Company’s growth and contribute my expertise to realize the enormous potential of its platform to treat a wide range of diseases affecting millions of patients that currently have limited or no therapeutic options.”

Prior to joining NeuBase, Mr. Branning was CFO of Phathom Pharmaceuticals, Inc., a publicly traded late clinical-stage biopharmaceutical company. Before that, he was Senior Vice President, CFO of Amneal Pharmaceuticals, Inc., a publicly traded pharmaceutical company, where he helped to build, leverage, and optimize infrastructure following the completion of a transformational merger. Prior to joining Amneal, he was Senior Vice President, CFO of the global generic medicines division at Teva Pharmaceutical Industries Ltd., a multinational generic pharmaceuticals company, where he led the finance function and served on the leadership team responsible for managing the day-to-day operations of Teva's largest multi-billion-dollar commercial unit. Mr. Branning has also held financial leadership roles at Allergan plc, PricewaterhouseCoopers LLP, PPG Industries, Inc., and Merck & Co., Inc. Mr. Branning received his BBA from the University of Miami and MBA from Carnegie Mellon University. Mr. Branning is also a Certified Public Accountant and has completed a CFO certification program at The Wharton School at the University of Pennsylvania.

About NeuBase Therapeutics
NeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines that Drug the Genome™. The Company’s therapies are built on a proprietary platform called PATrOL™ that encompasses a novel peptide-nucleic acid antisense oligonucleobase technology combined with novel delivery shuttles that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular, and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions, who currently have limited to no treatment options.